The authors describe CHAPERONE-CKM, an explainable, clinician-supervised artificial intelligence implementation framework designed to support multidisciplinary population health management for cardiovascular-kidney-metabolic (CKM) syndrome. CKM is framed as a multisystem condition linked to increased morbidity, fragmented care, recurrent hospitalization, and rising costs. The framework aims to go beyond traditional risk prediction by generating actionable outputs for clinicians and care teams to support coordinated CKM care, decision-making, and population-level prioritization.
Validation was performed using a reproducible synthetic cohort of 10,090 simulated patients. The dataset included 128 variables spanning demographics, laboratory measures, imaging results, treatments, and healthcare utilization across the CKM continuum. Synthetic data generation was deliberately separated from framework evaluation: probabilistic modeling and independent validation steps were used to reduce deterministic relationships between data generation and framework assessment, and to preserve privacy by avoiding identifiable human data.
The framework produced multiple implementation-oriented outputs intended for clinician and team use:
The framework emphasizes explainability and clinician supervision rather than autonomous decision-making.
Evaluation prioritized implementation readiness over classical predictive performance as proof of clinical effectiveness. Key evaluation domains included:
Traditional performance metrics were used as supporting evidence but explicitly treated as secondary to implementation-focused assessments.
Within the synthetic cohort, prevalences reflective of CKM-related conditions were reported: diabetes in 52% of simulated patients, hypertension in 65%, chronic kidney disease in 20%, heart failure in 32%, and prior CKM hospitalization in 27%. These characteristics contextualized framework behavior and the scope of population-level prioritization.
In the synthetic validation environment, the CHAPERONE-CKM framework demonstrated: favorable calibration and biologically plausible prioritization that favored detection of more advanced CKM disease; stable internal behavior across demographic and clinical subgroups; and subgroup stability consistent with the framework’s design. The authors report that these behaviors supported the framework’s implementation readiness in a synthetic setting.
Workflow simulations conducted within the synthetic environment indicated that CHAPERONE-CKM could enable earlier identification of patients appropriate for multidisciplinary review, earlier opportunities for therapy optimization, and more coordinated care relative to simulated reactive workflows. These simulated improvements were offered as evidence of potential operational benefits rather than proof of improved clinical outcomes.
The authors are explicit that these findings represent an early translational milestone achieved in a synthetic-data environment and do not constitute clinical validation. The report emphasizes that synthetic validation assesses implementation readiness, transparency, and internal behavior, but cannot replace external validation or prospective clinical studies. Additionally, the software framework and implementation engine are proprietary; although synthetic data specifications and analytical workflows will be shared on request, proprietary algorithms are protected, which may affect reproducibility of the full system by external groups.
Based on the synthetic validation results, the authors recommend further work including external validation, prospective implementation studies, and integration into Learning Health Systems. These steps are framed as necessary to evaluate effects on care delivery, equity, and value-based outcomes in real clinical settings and to move from implementation readiness to demonstrated clinical effectiveness.
The preprint reports that the broader CHAPERONE-CKM study was conducted in accordance with the Declaration of Helsinki and ICH Good Clinical Practice and that the protocol was reviewed and approved by Elemental Independent Review Board. Phase Ib used only synthetic records and did not require separate informed consent. The authors declared no competing interests. The ClinicalTrials.gov identifier provided in the preprint is NCT07403669. The complete software framework is proprietary; synthetic data specifications, variable definitions, and analytical workflows sufficient to reproduce the published analyses will be made available upon reasonable request while protecting proprietary algorithms.
Conclusion
In a synthetic patient environment of 10,090 simulated records, the CHAPERONE-CKM framework demonstrated explainable, clinician-supervised outputs, stable internal behavior across subgroups, favorable calibration, and workflow-simulation evidence suggesting earlier multidisciplinary identification and care coordination compared with reactive workflows. The authors stress these results are not clinical validation and call for external validation and prospective studies to determine real-world impacts on CKM care, equity, and outcomes.